Characterization of low level viraemia in HIV-infected patients receiving boosted protease inhibitor-based antiretroviral regimens
To understand the pathogenesis of low level viraemia (LLV) in HIV-infected patients on boosted protease inhibitors (PI/b), we enrolled 34 subjects with a median HIV-RNA 79 copies/mL and followed them for 15 months. Samples for next generation sequencing were collected at three time-points. Two showe...
Main Authors: | Francesca Ferretti, Nicola E. Mackie, Gurmit Kaur Jagjit Singh, Julie Fox, Steve Kaye, Myra O. McClure, Graham Taylor, Marta Boffito |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-09-01
|
Series: | HIV Research & Clinical Practice |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/25787489.2020.1716159 |
Similar Items
-
Potential Associations of Mutations within the HIV-1 <i>Env</i> and <i>Gag</i> Genes Conferring Protease Inhibitor (PI) Drug Resistance
by: Ntombikhona F. Maphumulo, et al.
Published: (2021-12-01) -
Low-level viraemia despite emergence of dolutegravir-resistant variants
by: Johannes C. Botha, et al.
Published: (2022-09-01) -
Spontaneous Mutations in HIV-1 Gag, Protease, RT p66 in the First Replication Cycle and How They Appear: Insights from an In Vitro Assay on Mutation Rates and Types
by: Joshua Yi Yeo, et al.
Published: (2020-12-01) -
Kidney Transplant-Associated Viral Infection Rates and Outcomes in a Single-Centre Cohort
by: Kairi Pullerits, et al.
Published: (2022-10-01) -
The HIV-1 Gag Protein Displays Extensive Functional and Structural Roles in Virus Replication and Infectivity
by: Veronna Marie, et al.
Published: (2022-07-01)